Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

Most of her recent buys have primarily focused on technology stocks, with American software giant Palantir (NYSE: PLTR) ...

Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering ...

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight ...

Hims & Hers Health (HIMS) stock crashes even as the company reported better than expected Q4 2024 results and issued a bullish outlook. Read more here.

Citi raised the firm’s price target on Hims & Hers to $27 from $25 and keeps a Sell rating on the shares post the Q4 report. The focus on ...

Comes after Bombay High Court took cognisance of woman’s petition; in filing to Bombay Stock Exchange, Jubilant Foodworks ...

"It must be so strange to be in a drainage pipe, and then all of a sudden be in a warm house," one social media user commented.

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...